Compare WINA & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WINA | ZYME |
|---|---|---|
| Founded | 1988 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2006 | 2022 |
| Metric | WINA | ZYME |
|---|---|---|
| Price | $418.13 | $24.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $38.90 |
| AVG Volume (30 Days) | 64.6K | ★ 647.9K |
| Earning Date | 04-15-2026 | 03-02-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | 3.76 | ★ 33.33 |
| EPS | ★ 11.30 | N/A |
| Revenue | $86,055,700.00 | ★ $105,965,000.00 |
| Revenue This Year | $5.55 | $162.82 |
| Revenue Next Year | $6.03 | N/A |
| P/E Ratio | $37.98 | ★ N/A |
| Revenue Growth | 5.86 | ★ 38.87 |
| 52 Week Low | $295.79 | $9.03 |
| 52 Week High | $526.81 | $28.49 |
| Indicator | WINA | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 42.46 | 52.58 |
| Support Level | $405.17 | $22.28 |
| Resistance Level | $451.93 | $27.54 |
| Average True Range (ATR) | 19.63 | 1.20 |
| MACD | -1.60 | 0.04 |
| Stochastic Oscillator | 20.69 | 32.68 |
Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment including Franchising and one non-reportable segment Leasing. The franchising segment franchises value-oriented retail store that buys, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.